Laventair Ellipta

Umeclidinium bromide / Vilanterol, the active ingredient in Laventair Ellipta, is a long‑acting muscarinic antagonist combined with a long‑acting β2‑agonist presented as an inhalation powder for inhalation use. It is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients, helping to improve lung function and reduce symptoms.

GNH USA supplies Laventair Ellipta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Laventair Ellipta is used in the management of chronic obstructive pulmonary disease (COPD), a progressive airway disease characterized by airflow limitation. - Chronic obstructive pulmonary disease (COPD): provides long‑term bronchodilation to improve airflow and reduce symptom burden. - Stable COPD: helps decrease the frequency of exacerbations. - COPD with persistent symptoms: enhances lung function and quality of life.

Laventair Ellipta may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported. - Cough: transient cough after inhalation. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Dry mouth: reduced salivation leading to oral dryness.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing requiring medical attention. - Cardiovascular events: palpitations, tachycardia, or arrhythmias. - Allergic reactions: rash, angioedema, or anaphylaxis.

Before prescribing Laventair Ellipta, clinicians should consider several precautionary measures to ensure safe use. - Assess cardiovascular status: evaluate for uncontrolled arrhythmias or recent myocardial infarction. - Review respiratory history: avoid in patients with severe hypersensitivity to components. - Monitor for paradoxical bronchospasm: discontinue if symptoms worsen. - Caution in hepatic impairment: adjust monitoring as metabolism may be affected. - Use with other bronchodilators: consider additive effects on heart rate. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Laventair Ellipta can interact with other medicines, and awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Beta‑blockers: may reduce bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): increased risk of cardiovascular effects. - Anticholinergic drugs: additive anticholinergic burden may cause dry mouth or urinary retention.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalemia risk when combined with β2‑agonist. - Theophylline: possible increase in plasma levels leading to toxicity. - Antihistamines: may increase anticholinergic side effects.